Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines, with revenue of $11.19B vs. $10.63B expected and normalized EPS of $2.14 vs. $2.05 expected. The International Smoke-Free segment was the primary driver, growing 14.2% YoY, while modern oral products showed 14.7% growth outside the Nordics. Despite a $511M non-cash impairment related to the RBH investment, management raised full-year guidance for shipment volumes, signaling confidence in the continued smoke-free transformation.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Phillip Morris(PM) the Revenue is 11.19 B (+10.37%), Beat estimate;the EBIT is 4.773 B (+12.41%), Beat estimate;the EPS is 1.8 (-7.69%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
11.19B10.37%
10.63B4.85%
+0.56B5.52%
EBITExceed expectations
4.77B12.41%
4.44B4.61%
+0.33B7.80%
EPSMiss expectations
1.87.69%
1.9680.93%
-0.16808.62%
Upcoming earnings report - Q3 FY2026
Available dateOct 21, 2026
Estimate Revenue$11.25 B
Estimate EBIT$4.784 B
Estimate EPS$2.1076
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf